Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
However, these won’t be available at the nearest chemist store soon
First launches expected in H1 2022
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
This test analyses samples in VTM directly without the need for RNA extraction step
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
Subscribe To Our Newsletter & Stay Updated
